Every Monday Is A Zecyte Monday

Zecyte has received approval from the Drug Controller General of India (DCGI) for treating chemo-naïve metastatic castrate resistant prostate cancer. This indicates that the statement is true.

Zecyte is an inhibitor of CYP17. CYP17 is an enzyme involved in the production of androgens, which are male sex hormones. By inhibiting CYP17, Zecyte can effectively reduce the production of androgens, which is beneficial in the treatment of certain hormone-sensitive cancers such as prostate cancer.

The correct answer is "Digital rectal examination." This procedure involves a doctor inserting a gloved, lubricated finger into the rectum to check for abnormalities in the rectum, prostate, and other nearby organs. It is commonly used to detect prostate cancer, evaluate rectal bleeding, and diagnose other conditions such as hemorrhoids or rectal tumors.

Zecyte should not be taken with food. It is recommended to take Zecyte on an empty stomach, at least one hour before or two hours after a meal. Taking Zecyte with food may decrease its effectiveness and absorption into the body. Therefore, the correct answer is False.

The recommended daily dose of Zecyte is 250 mg four times a day. This means that a total of 1000 mg of Zecyte should be taken in a day, with each dose being 250 mg. Taking the medication four times a day helps maintain a consistent level of the drug in the body, ensuring its effectiveness. Both options B and C suggest the correct dosage of 250 mg, but option B specifies the frequency of four times a day, making it the most accurate answer.

The target population for zecyte includes both chemo-naïve metastatic castrate resistant patients and chemo-resistant metastatic castrate resistant patients. This means that the medication is suitable for patients who have not received chemotherapy before as well as those who have previously received chemotherapy but are still experiencing metastatic castrate resistance.

The PSA level is not a reliable predictor of who can get cured with prostate surgery. While a high PSA level may indicate the presence of prostate cancer, it does not guarantee that surgery will be successful in curing the disease. Other factors such as the stage and aggressiveness of the cancer, as well as the overall health of the patient, need to be considered when determining the effectiveness of surgery as a treatment option. Therefore, the statement is false.

The statement "All men should be tested for prostate cancer" is not true. Prostate cancer screening involves a PSA blood test and a digital rectal exam, both of which have potential risks and limitations. The decision to be tested should be based on an individual's age, health status, and personal preferences, as well as a discussion with their healthcare provider. Screening is not recommended for all men, as the potential benefits may not outweigh the harms for those at low risk. Therefore, the correct answer is False.

A PSA level under 4 ng/ml does not necessarily mean that the patient does not have prostate cancer. While a PSA level under 4 ng/ml is generally considered normal, it does not completely rule out the possibility of prostate cancer. Other factors such as the patient's age, medical history, and symptoms should also be taken into consideration when determining the presence or absence of prostate cancer. Therefore, the statement that a PSA level under 4 ng/ml means the patient does not have prostate cancer is false.

Abiraterone is not indicated for chemo-naïve hormone-sensitive prostate cancer. It is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC), either before or after chemotherapy. Therefore, the statement that Abiraterone is indicated for chemo-naïve hormone-sensitive prostate cancer is false.